Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 May 2018

June 1, 2018 – The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended nine medicines for approval, including two orphan medicines1, at its May 2018 meeting. The CHMP recommended granting a marketing authorisation for Erenumab, the first human monoclonal antibody therapy for prevention of migraine. Erenumab belongs to a new class of medicines that work by blocking the activity of calcitonin … (leggi tutto)